Hyderabad-based Aragen Life Sciences acquires Intox

Hyderabad: Hyderabad-based Aragen Life Sciences, a research, development, and manufacturing solutions provider (CRO/CDMO) signed a definitive agreement to acquire Pune-based Intox.  This acquisition will expand Aragen’s end-to-end integrated discovery and development platform for the pharmaceuticals, biotechnology, animal health, and agrochemicals industries. It will also enable Aragen to conduct safety assessment studies from a Good Laboratory […]

Hyderabad: Hyderabad-based Aragen Life Sciences, a research, development, and manufacturing solutions provider (CRO/CDMO) signed a definitive agreement to acquire Pune-based Intox. 

This acquisition will expand Aragen’s end-to-end integrated discovery and development platform for the pharmaceuticals, biotechnology, animal health, and agrochemicals industries.

---

It will also enable Aragen to conduct safety assessment studies from a Good Laboratory Practice (GLP)-certified facility for submission to regulatory agencies such as the United States Food and Drug Administration (USFDA), the United States Environmental Protection Agency (USEPA), the European Medicines Agency (EMA), and others globally.

Intox is a GLP certified pre-clinical contract research organisation (CRO) with its test facilities in Pune. It has conducted more than 15,000 GLP studies for global clients, which include large and mid-sized customers across pharmaceuticals, biopharmaceuticals, plant protection, nutraceuticals, and medical devices.

Commenting on the acquisition, Manni Kantipudi, CEO, Aragen Life Sciences, said, “This acquisition is in strategic alignment with our long-term vision to be a ‘one-stop’ integrated discovery, development, and manufacturing partner to our customers.”

“We can, now, rapidly and seamlessly, advance promising molecules for our customers, from early discovery to Investigational New Drug (IND) submissions, making Aragen one of the few global CROs that can advance programs from concept-to-clinic,” Kantipudi added.

The acquisition will also expand Aragen’s geographical footprint in India. Aragen currently has research and manufacturing facilities at Hyderabad, Bengaluru, and Vizag in India and a biologics facility in California, USA.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .